Table of Content

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Osteoporosis Drugs Market, by Route of Administration
1.4.2 North America Osteoporosis Drugs Market, by Drug Class
1.4.3 North America Osteoporosis Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Osteoporosis Drugs Market by Route of Administration
3.1 North America Oral Market by Country
3.2 North America Injectable Market by Country
3.3 North America Other Route of Administration Market by Country
Chapter 4. North America Osteoporosis Drugs Market by Drug Class
4.1 North America Bisphosphonates Market by Country
4.2 North America Rank Ligand Inhibitors Market by Country
4.3 North America Parathyroid Hormone Therapy Market by Country
4.4 North America Calcitonin Market by Country
4.5 North America Other Drug Class Market by Country
Chapter 5. North America Osteoporosis Drugs Market by Country
5.1 US Osteoporosis Drugs Market
5.1.1 US Osteoporosis Drugs Market by Route of Administration
5.1.2 US Osteoporosis Drugs Market by Drug Class
5.2 Canada Osteoporosis Drugs Market
5.2.1 Canada Osteoporosis Drugs Market by Route of Administration
5.2.2 Canada Osteoporosis Drugs Market by Drug Class
5.3 Mexico Osteoporosis Drugs Market
5.3.1 Mexico Osteoporosis Drugs Market by Route of Administration
5.3.2 Mexico Osteoporosis Drugs Market by Drug Class
5.4 Rest of North America Osteoporosis Drugs Market
5.4.1 Rest of North America Osteoporosis Drugs Market by Route of Administration
5.4.2 Rest of North America Osteoporosis Drugs Market by Drug Class
Chapter 6. Company Profiles
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.1.4 Recent strategies and developments:
6.1.4.1 Partnerships, Collaborations, and Agreements:
6.1.4.2 Approvals:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 GlaxoSmithKline PLC (GSK)
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.4 Merck & Co., Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expenses
6.5 Novartis AG
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Recent strategies and developments:
6.5.4.1 Partnerships, Collaborations, and Agreements:
6.6 Pfizer, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Sun Pharmaceutical Industries Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Teva Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expenses
6.9 Allergan PLC
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.1 Eli Lilly and Company
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense



List of Tables


TABLE 1 NORTH AMERICA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 2 NORTH AMERICA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 3 NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 4 NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 5 NORTH AMERICA ORAL MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 6 NORTH AMERICA ORAL MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 7 NORTH AMERICA INJECTABLE MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 8 NORTH AMERICA INJECTABLE MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 9 NORTH AMERICA OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 10 NORTH AMERICA OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 11 NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 12 NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 13 NORTH AMERICA BISPHOSPHONATES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 14 NORTH AMERICA BISPHOSPHONATES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 15 NORTH AMERICA RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 16 NORTH AMERICA RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 17 NORTH AMERICA PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 18 NORTH AMERICA PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 19 NORTH AMERICA CALCITONIN MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 20 NORTH AMERICA CALCITONIN MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 21 NORTH AMERICA OTHER DRUG CLASS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 22 NORTH AMERICA OTHER DRUG CLASS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 23 NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 24 NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 25 US OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 26 US OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 27 US OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 28 US OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 29 US OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 30 US OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 31 CANADA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 32 CANADA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 33 CANADA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 34 CANADA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 35 CANADA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 36 CANADA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 37 MEXICO OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 38 MEXICO OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 39 MEXICO OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 40 MEXICO OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 41 MEXICO OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 42 REST OF NORTH AMERICA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 43 REST OF NORTH AMERICA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 44 REST OF NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 45 REST OF NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 46 REST OF NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 47 REST OF NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 48 KEY INFORMATION – AMGEN, INC.
TABLE 49 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 50 KEY INFORMATION – GLAXOSMITHKLINE PLC (GSK)
TABLE 51 KEY INFORMATION - MERCK & CO., INC.
TABLE 52 KEY INFORMATION – NOVARTIS AG
TABLE 53 KEY INFORMATION – PFIZER, INC.
TABLE 54 KEY INFORMATION – SUN PHARMACEUTICAL INDUSTRIES LTD.
TABLE 55 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 56 KEY INFORMATION – ALLERGAN PLC
TABLE 57 KEY INFORMATION – ELI LILLY AND COMPANY

LIST OF FIGURES

FIG 1 METHODOLOGY FOR THE RESEARCH